Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

Laurette van Boheemen; Samina Turk; Marian van Beers-Tas; Wouter Bos; Diane Marsman; Ed N Griep; Mirian Starmans-Kool; Calin D Popa; Alper van Sijl; Maarten Boers; Michael T Nurmohamed; Dirkjan van Schaardenburg

doi:10.1136/rmdopen-2021-001591

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest Content

Archive

For authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

Rheumatoid arthritis

Short report

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: van Boheemen L, Turk S, Beers-Tas MV, et al

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

RMD Open 2021;7:e001591. doi: 10.1136/rmdopen-2021-001591

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password